

OFFICE OF THE SECRETARY OF STATE  
TOBIAS READ  
SECRETARY OF STATE  
  
MICHAEL KAPLAN  
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION  
STEPHANIE CLARK  
DIRECTOR  
  
800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

**NOTICE OF PROPOSED RULEMAKING**  
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855  
**BOARD OF PHARMACY**

**FILED**  
04/15/2026 11:22 AM  
ARCHIVES DIVISION  
SECRETARY OF STATE

FILING CAPTION: Medications for Opioid Use Disorder Protocols; Continuation of Therapy

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 05/26/2026 4:30 PM

*The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.*

CONTACT: Rachel Melvin  
971-673-0001  
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150  
Portland, OR 97232

Filed By:  
Rachel Melvin  
Rules Coordinator

HEARING(S)

*Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.*

DATE: 05/26/2026

TIME: 9:30 AM

OFFICER: Rachel Melvin

REMOTE HEARING DETAILS

MEETING URL: [Click here to join the meeting](#)

PHONE NUMBER: 503-446-4951

CONFERENCE ID: 275861032

SPECIAL INSTRUCTIONS:

This hearing will be held virtually via Microsoft Teams.

If you wish to present oral testimony virtually during this hearing, sign up on our website at [www.oregon.gov/pharmacy/pages/rulemaking-information](http://www.oregon.gov/pharmacy/pages/rulemaking-information) or email your first and last name and email address to [pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov). Please indicate which rule(s) you would like to comment on. You must submit written comments before 4:30PM on May 26, 2026. Email written comments to [pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov).

NEED FOR THE RULE(S)

Proposes permanently adopting revised version of Continuation of Therapy protocol and adds new protocols for Medications for Opioid Use Disorder (MOUD) for Initiation of Care and Continuation/Modification of Care.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

ORS 689.698 [https://www.oregonlegislature.gov/bills\\_laws/ors/ors689.html](https://www.oregonlegislature.gov/bills_laws/ors/ors689.html)

Preventive Care: Medications for Opioid Use Disorder (MOUD) - Initiation of Care

[https://www.oregon.gov/pharmacy/Documents/MOUD\\_Initiation\\_of\\_Care\\_Protocol\\_v.02.2026.pdf](https://www.oregon.gov/pharmacy/Documents/MOUD_Initiation_of_Care_Protocol_v.02.2026.pdf)

REQUIRED Instruction Sheet - Print for Patient

[https://www.oregon.gov/pharmacy/Documents/REQUIRED\\_MOUD\\_Initiation\\_of\\_Care\\_4\\_Instruction\\_Sheet\\_v.02.2026.pdf](https://www.oregon.gov/pharmacy/Documents/REQUIRED_MOUD_Initiation_of_Care_4_Instruction_Sheet_v.02.2026.pdf)

Preventive Care: Medications for Opioid Use Disorder (MOUD) - Continuation/Modification of Care

[https://www.oregon.gov/pharmacy/Documents/MOUD\\_Continuation\\_or\\_Modification\\_of\\_Care\\_Protocol\\_v.02.2026.pdf](https://www.oregon.gov/pharmacy/Documents/MOUD_Continuation_or_Modification_of_Care_Protocol_v.02.2026.pdf)

---

#### STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

The proposed rule may increase Oregonians access to opioid use disorder medications.

---

#### FISCAL AND ECONOMIC IMPACT:

No fiscal anticipated. Licensees, registrants and interested parties will have an opportunity to provide fiscal and economic impact statements during the open comment period.

---

#### COST OF COMPLIANCE:

*(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).*

The proposed rule amendments will have no anticipated additional economic impact on state agencies, units of local government, the public or registrants or licensees who identify as a small business.

---

#### DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Registrants who identify as a small business and who have signed up to receive rulemaking notices will receive an email notice of proposed rulemaking via GovDelivery and will have an opportunity to provide public comment on the proposed rules for the board's consideration.

---

#### WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

Legislative mandate of 2025 SB 236 and Subject Matter Experts (SME) are responsible for drafting proposed or amended protocols and the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC) is responsible for recommending proposed or amended protocols to the Board for consideration.

---

AMEND: 855-115-0345

**RULE SUMMARY:** Amends (1) by revising the Continuation of Therapy protocol by removing language related to early refills of non-controlled opioid use disorder medications as mandated by revised statutory language. Proposes adopting two new protocols in (3)(j)(k) for Medications for Opioid Use Disorder (MOUD) for Initiation of Care and Continuation/Modification of Care as mandated by 2025 SB 236 (ORS 689.698).

#### CHANGES TO RULE:

855-115-0345

Services: Prescribing Pursuant to - Protocol

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

<https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>. Pharmacists can prescribe pursuant to the protocols listed below.

(1) Continuation of ~~the~~ Therapy Protocol including emergency refills of insulin and ~~early refills of opioid use disorder~~

medications (v. 08/2024).¶

(2) Conditions Protocols:¶

(a) Cough and cold symptom management:¶

(A) Benzonatate (v. 06/2021);¶

(B) Short-acting beta agonists (v. 06/2021);¶

(C) Intranasal corticosteroids (v. 06/2021);¶

(b) COVID-19 Antigen Self-Test (v. 12/2021);¶

(c) SARS-CoV-2 Antiviral (v. 08/2024).¶

(3) Preventative Care Protocols:¶

(a) Emergency Contraception (v. 06/2021);¶

(b) Male and female condoms (v. 06/2021);¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);¶

(d) Travel Medications (v. 06/2024);¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 01/2026);¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 01/2026); ¶

(g) Contraception (v. 06/2025);¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and¶

(j) Medications for Opioid Use Disorder - Initiation of Care (v. 02/2026); and¶

(k) Medications for Opioid Use Disorder - Continuation/Modification of Care (v. 02/2026). ¶

(4) Vaccine Protocols:¶

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 01/2026);¶

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 01/2026); and¶

(c) Vaccination Protocol for Managing Adverse Reactions (v. 08/2025).¶

(5) Board Excluded Vaccine Protocols:¶

(a) Coronavirus 19 (v. 01/2026);¶

(b) Influenza (v. 01/2026); and¶

(c) Respiratory Syncytial Virus (v. 09/2025). ¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, ORS 689.005, ORS 689.698

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005, ORS 689.698